Harrow Inc
HROW37.480USD
-3.090-7.62%
Handelsschluss 10/10, 16:00（ET）Kurse um 15 Minuten verzögert
1.38BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Harrow Inc Unternehmen
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc Informationen
BörsenkürzelHROW
Name des UnternehmensHarrow Inc
IPO-datumFeb 08, 2013
CEOMr. John P. Saharek
Anzahl der mitarbeiter382
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 08
Addresse1A Burton Hills Blvd
StadtNASHVILLE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl37215
Telefon16157334731
Websitehttps://www.harrow.com/
BörsenkürzelHROW
IPO-datumFeb 08, 2013
CEOMr. John P. Saharek
Führungskräfte von Harrow Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Sales Net
63.66M
0.00%
Transfer of acquired product sales/profit
85.00K
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Sales Net
63.66M
0.00%
Transfer of acquired product sales/profit
85.00K
0.00%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
Andere
65.27%
Aktionäre
Aktionäre
Anteil
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
Andere
65.27%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
18.79%
Investment Advisor
18.35%
Hedge Fund
17.30%
Individual Investor
15.72%
Research Firm
2.46%
Bank and Trust
0.35%
Pension Fund
0.29%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
Andere
26.64%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
346
21.34M
57.68%
-3.88M
2025Q2
345
26.63M
72.57%
-2.99M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Opaleye Management Inc.
3.90M
10.55%
-35.00K
-0.89%
Jun 30, 2025
Baum (Mark L)
2.89M
7.8%
+286.66K
+11.03%
Jul 21, 2025
BlackRock Institutional Trust Company, N.A.
2.25M
6.09%
-21.27K
-0.94%
Jun 30, 2025
Private Capital Management
1.95M
5.26%
+54.73K
+2.90%
Jun 30, 2025
The Vanguard Group, Inc.
1.86M
5.03%
+3.81K
+0.21%
Jun 30, 2025
Kaufman (Daniel)
1.68M
4.55%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
872.25K
2.36%
-84.59K
-8.84%
Jun 30, 2025
Geode Capital Management, L.L.C.
810.80K
2.19%
+36.72K
+4.74%
Jun 30, 2025
Boll (Andrew R)
777.84K
2.1%
+209.75K
+36.92%
Apr 21, 2025
State Street Global Advisors (US)
773.11K
2.09%
-13.38K
-1.70%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Oct 6
Aktualisiert: Mon, Oct 6
Name
Anteil
Invesco Dorsey Wright Healthcare Momentum ETF
2.04%
SPDR S&P Pharmaceuticals ETF
1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.41%
First Trust Small Cap Growth AlphaDEX Fund
0.59%
iShares U.S. Pharmaceuticals ETF
0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
First Trust Small Cap Core Alphadex Fund
0.29%
iShares Micro-Cap ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.15%
Mehr Anzeigen
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.04%
SPDR S&P Pharmaceuticals ETF
Anteil1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.41%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.59%
iShares U.S. Pharmaceuticals ETF
Anteil0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.44%
First Trust Small Cap Core Alphadex Fund
Anteil0.29%
iShares Micro-Cap ETF
Anteil0.25%
ProShares Ultra Nasdaq Biotechnology
Anteil0.15%
Invesco Nasdaq Biotechnology ETF
Anteil0.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
